Illumina, Inc.NASDAQ: ILMN

Illumina expands Billion Cell Atlas program with new AI drug developers

· Issued by Illumina, Inc. via PR Newswire

Summary by 6ix AI

On July 16, 2026, Illumina, Inc. said its Billion Cell Atlas alliance has added three new member companies, including Formation Bio, which Illumina describes as an AI-native drug developer.

Key details

  • Illumina says alliance members will use its genome-wide perturbation data (data from changing genes across the whole genome in cells and measuring the effects) as infrastructure for developing new therapeutics.
  • Illumina says the partners will use the data to advance more precise medicines to approval.

6ix AI wrote this summary from the release below and checked it against the release.

Partners will use unprecedented data scale to advance more precise medicines to approval

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics.

-->

Illumina, Inc. on 6ix

Story so far

Earlier from Illumina

Later from Illumina

All Illumina news releases